baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BIOGEN INC. DL -,0005/ US09062X1037 /

5/27/2024 9:20:28 AM	Chg. +0.40	Volume	Bid9:30:00 AM	Ask9:30:00 AM	Market Capitalization	Dividend Y.	P/E Ratio
200.80EUR	+0.20%	0 Turnover: 0.00	199.60Bid Size: 270	202.10Ask Size: 260	29.25 bill.EUR	-	-

GlobeNewswire 5/22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 5/21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 5/16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 5/15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 5/2 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 4/25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 4/24 Biogen posts Q1 revenue of $2.3 billion

GlobeNewswire 4/23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 4/2 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 3/6 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 3/4 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...

GlobeNewswire 2/23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

TeleTrader 2/13 Biogen's Q4 revenue falls 6% to $2.4 billion

GlobeNewswire 2/12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...

TeleTrader 2/12 Earnings preview: Robinhood, Coinbase and more

GlobeNewswire 2/8 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

GlobeNewswire 1/4 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer

GlobeNewswire 12/19/2023 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...

GlobeNewswire 12/15/2023 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...

GlobeNewswire 12/14/2023 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...

TeleTrader 11/8/2023 Biogen's Q3 revenue up 3% to $2.5B

GlobeNewswire 11/6/2023 Biogen Appoints Monish Patolawala to its Board of Directors

GlobeNewswire 10/25/2023 Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...

GlobeNewswire 10/25/2023 New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise f...

GlobeNewswire 10/19/2023 Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

BIOGEN INC. DL -,0005/ US09062X1037 /

If you wish to receive reply to your feedback, please provide your email address.